Acute sleep loss decreases CSF‐to‐blood clearance of Alzheimer's disease biomarkers
- 25 January 2023
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (7), 3055-3064
- https://doi.org/10.1002/alz.12930
Abstract
IntroductionSleep deprivation increases cerebrospinal fluid (CSF) amyloid beta (A beta) and tau levels; however, sleep's effect on A beta and tau in plasma is unknown. MethodsIn a cross-over design, CSF A beta and tau concentrations were measured in five cognitively normal individuals who had blood and CSF collected every 2 hours for 36 hours during sleep-deprived and normal sleep control conditions. ResultsA beta 40, A beta 42, unphosphorylated tau threonine181 (T181), unphosphorylated tau threonine-217 (T217), and phosphorylated T181 (pT181) concentrations increased similar to 35% to 55% in CSF and decreased similar to 5% to 15% in plasma during sleep deprivation. CSF/plasma ratios of all Alzheimer's disease (AD) biomarkers increased during sleep deprivation while the CSF/plasma albumin ratio, a measure of blood-CSF barrier permeability, decreased. CSF and plasma A beta 42/40, pT181/T181, and pT181/A beta 42 ratios were stable longitudinally in both groups. DiscussionThese findings show that sleep loss alters some plasma AD biomarkers by lowering brain clearance mechanisms and needs to be taken into account when interpreting individual plasma AD biomarkers but not ratios.Keywords
Funding Information
- National Institutes of Health (R03 AG047999, K76 AG054863, P50 AG05681, P01 AG26276)
- National Institute on Aging (R01 NS065667, R01 NS097799)
- National Institute of Neurological Disorders and Stroke
This publication has 40 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- Effects of Age and Amyloid Deposition on Aβ Dynamics in the Human Central Nervous SystemArchives of Neurology, 2012
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque PathologyArchives of Neurology, 2011
- Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the BrainJournal of Nuclear Medicine, 2009
- Blood–brain barrier impairment in Alzheimer diseaseNeurology, 2007
- P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse modelJCI Insight, 2005
- Generalized Linear Mixed ModelsPublished by Wiley ,2005
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- β‐Amyloid efflux mediated by p‐glycoproteinJournal of Neurochemistry, 2001